Eton launches IMPAVIDO treatment in U.S. market
- Eton Pharmaceuticals launched IMPAVIDO (miltefosine) capsules in the United States under exclusive commercialization rights.
- The treatment is approved for certain forms of leishmaniasis in patients aged 12 and older who weigh at least 30 kg.
- Eton said it expanded patient support through Eton Cares, including a $0 co-pay program for eligible commercially insured patients.
Eton Pharmaceuticals (NASDAQ:ETON) launched IMPAVIDO (miltefosine) capsules in the United States under exclusive U.S. commercialization rights for the treatment of certain forms of leishmaniasis.
The drug is indicated for visceral, cutaneous, and mucosal leishmaniasis in patients at least 12 years old who weigh at least 30 kg.
Eton said IMPAVIDO has been added to its Eton Cares program, which provides a $0 co-pay option for eligible commercially insured patients and expanded patient assistance, while Anovo Specialty Pharmacy will manage distribution and access coordination.
Eton Pharmaceuticals develops and commercializes pharmaceutical products across specialty markets, including treatments for rare diseases and other medical conditions.
The company noted that IMPAVIDO carries safety warnings, including a contraindication during pregnancy due to potential fetal harm and reports of Stevens-Johnson syndrome.
Frequently asked questions
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
